Logo
x

Search

Subscribe Now

ultragenyx

Ultragenyx Reports the EC’s Approval of Evkeeza (evinacumab) to Treat 6-Months Old Children with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Reports the EC’s Approval of Evkeeza (evinacumab) to Treat 6-Months Old Children with Homozygous Familial Hypercholeste...

  • January 6, 2025
Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholest...

  • December 19, 2023
Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in the P-III Program for Osteogenesis Imperfecta

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in the P-III Program for Osteogenesis Imperfecta

  • July 7, 2023
Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A

Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A

  • May 18, 2022
Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Imperfecta

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Impe...

  • April 21, 2022
PharmaShots Interview: n-Lorem Foundation's Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients

PharmaShots Interview: n-Lorem Foundation's Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide...

  • June 15, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.